Use of Methazolamide to Lower Intraocular Pressure


The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: July 31, 2023


  • Drug: Methazolamide 25 MG
    • 25 mg tablets
  • Drug: Methazolamide 50 MG
    • 50 mg tablets

Arms, Groups and Cohorts

  • Active Comparator: Methazolamide 25 mg
    • Once a day [q.d] in the morning for 1 week, Twice a day [b.i.d.] in the morning and evening for 1 week
  • Active Comparator: Methazolamide 50 mg
    • Once a day [q.d] in the morning for 1 week, Twice a day [b.i.d.] in the morning and evening for 1 week

Clinical Trial Outcome Measures

Primary Measures

  • Percent IOP change at each follow-up Visit
    • Time Frame: Day 1 (Pre-dosing, then 4- and 8- hours post dosing), Day 7 (Pre-dosing, then 4- and 8- hours post dosing), Day 14 (Pre-dosing, then 4- and 8- hours post dosing)
    • IOP measure is measured using Goldmann Tonometry. IOP is measured in mmHg with a normal range from 12 mmHg to 22 mmHg.

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females between 50 and 90 years old – Current diagnosis of open angle glaucoma (OAG) in both eyes – Ability to read and write in English Exclusion Criteria:

  • Glaucoma other than OAG – Severe or end-stage glaucoma (cup to disc ratio >0.8 or Mean Deviation on Visual Field worse than -12) – Pregnant or breast-feeding women

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Colorado, Denver
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Malik Y. Kahook, MD, Principal Investigator, University of Colorado, Denver
  • Overall Contact(s)
    • Sarah M. Wilting, OD, 720-848-6989,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.